Kisspeptin and LH Pulses in Women With Hyperprolactinemia
Eleven women with hyperprolactinemia completed intensive sampling visits designed to examine LH pulsatility with and without repeated kisspeptin administration.
Study design
Blood was sampled every ten minutes across two 12-hour visits. One visit assessed baseline pulsatility; during the other, kisspeptin 112-121 was administered hourly for ten hours before a GnRH bolus.
What the researchers reported
Repeated kisspeptin administration increased the number of detected LH pulses and shortened the interpulse interval. Pulse amplitude did not change, while mean LH increased; most participants had an LH pulse within 30 minutes of the first dose.
What this result does not establish
This small physiological study used LH as a proxy for GnRH activity and did not assess pregnancy, long-term reproductive outcomes or long-term safety.
This article summarizes one published study about Kisspeptin. It does not establish clinical efficacy, general safety, regulatory approval or suitability for human use. Findings should be interpreted within the model, methods and limitations of the original paper.
Related research material
Review the corresponding catalogue listing, labelled amount and available documentation. The study may use a different formulation or experimental preparation; it does not verify our product, its batch or suitability for human use.
Our Approach
Evidence before assumption.
TAM Global Research focuses on transparent documentation, careful scientific interpretation and clear distinction between what available evidence supports and what requires further verification.
Explore our quality standards